Author/Authors :
Rakhsha Afshin نويسنده , Yousefi Kashi Amir Shahram نويسنده Department of Radiation Oncology, Shohada-e-Tajrish
Hospital, Faculty of Medicine, Shahid Beheshti University of Medical
Sciences, Tehran, IR Iran , Razzaghdoust Abolfazl نويسنده Cancer Researcher, Department of Radiation Oncology,
Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical
Sciences, Tehran, IR Iran
Abstract :
Background Colorectal cancer is one major health problem and
cancer-related cause of death in cancer patients in countries such as
Iran where the most cases are diagnosed in advanced stages. Objectives
To evaluate the incidence and severity of toxic effects in colorectal
cancer patients who have been treated with two different schedules of
combination of oxaliplatin and bolus/infusional 5-fluorouracil with
leucovorin (FOLFOX) and to compare them. Methods Medical records of 458
patients with colorectal cancer treated with FOLFOX 4 and modified
FOLFOX 6 regimen between 2005 and 2014 were reviewed. Data from 96
eligible patients were analyzed. Fifty-six patients (58.3%) received
FOLFOX 4 and 40 patients (41.7%) received modified FOLFOX 6. Results The
study included 96 patients, 39 of whom were males (40.6%) and 57 of whom
were females (59.4%). The median age was 62 years (range: 38 - 87
years). The follow up duration was between 16 - 109 months with a median
of 62 months. There was a statistically significant incidence rate of
grade ≥ 1 toxicity of diarrhea as gastrointestinal (GI) toxicity between
FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.034), but
there was not a statistically significant incidence rate of grade ≥ 1
toxicity of stomatitis as GI toxicity between the two regimens (P =
0.27). We observed a highly statistically significant incidence rate of
grade ≥ 1 toxicity of neutropenia as hematologic toxicity between FOLFOX
4 and modified FOLFOX 6 as the two regimens (P < 0.001), but we
did not observe any statistically significant differences of grade ≥ 1
of thrombocytopenia as hematologic toxicity between the two regimens (P
= 0.063). There was a statistically significant incidence rate of grade
≥ 1 neurotoxicity between FOLFOX 4 and modified FOLFOX 6 as the two
regimens (P = 0.017). Conclusions We showed that in colorectal cancer
patients treated with modified FOLFOX6. Some of hematological and
non-hematological complications were more than FOLFOX4 and they can be
concerned.
